Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Are There Risks With Early-term Birth?
    ABSTRACT & COMMENTARY

    Are There Risks With Early-term Birth?

    Infant incubator
    December 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Long-term Multivitamin Use in Older Men: Are There Benefits for the Brain?

    Are you concerned about infection, infertility risks with IUD? You can relax

    Maternal Complications with Vaginal Birth After Cesarean Delivery: A Multicenter Study

    Keywords

    pregnancy

    delivery

    early-term

    By John C. Hobbins, MD

    Professor, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora

    Dr. Hobbins reports no financial relationships relevant to this field of study.

    SYNOPSIS: The authors of a multicenter study suggest that composite neonatal outcome is worse when pregnancy is interrupted in uncomplicated pregnancies at 37 to 38 weeks, even with documented fetal lung maturity, compared to pregnancies delivered at full term (39 to 40 weeks).

    SOURCE: Tita ATN, Jablonski K, Bailit JL, et al. Neonatal outcomes of elective early-term births after demonstrated fetal lung maturity. Am J Obstet Gynecol 2018;219:296.e1-296.e8.

    In a blockbuster study that was covered in the April 2018 issue of OB/GYN Clinical Alert, Grobman et al suggested that intervention at 39 weeks in well-dated, seemingly normal pregnancies improves perinatal outcome.1 So, why not push back the envelope further to 37-38 weeks?

    These researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network evaluated data from 11,502 patients in 25 hospitals from 2008 to 2011, where, on occasion, patients were induced between 37 and 38 weeks for no obvious indications other than having a positive amniotic fluid test for fetal lung maturity. Tita et al compared neonatal outcomes with 47,957 full-term births in the overall patient population of uncomplicated pregnancies. Fetal pulmonic maturity testing was conducted on 180 of the early-term “normal” patients and they were delivered. The authors studied a variety of adverse outcome measures, including continuous positive airway pressure (CPAP), transient tachypnea of the newborn (TTN), sepsis, hypoglycemia, hyperbilirubinemia, and five-minute Apgar scores < 7. Other variables included newborn intensive care unit (NICU) admission and the need to stay there longer than two days.

    For the early-term deliveries, the investigators noted significant increases in the need for CPAP (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.91-8.0), hyperbilirubinemia (OR, 3.0; 95% CI, 1.8-5.0), TTN (OR, 5.5; 95% CI, 3.3-9.1), NICU admissions (OR, 2.8; 95% CI, 1.8-4.5), and > 2-day length of stay (OR, 4.3; 95% CI, 2.4-7.7). The composite adverse neonatal outcome was significantly worse in the early-term delivery group (OR, 3.2; 95% CI, 2.1-4.8) and remained significant (OR, 3.5; 95% CI, 1.8-6.5) when propensity score matching was applied (early-term deliveries were more common in non-Hispanic whites, smokers, and those given steroids).

    COMMENTARY

    Term has been defined as a pregnancy lasting more than 36 weeks. This has been divided into early-term (37 to 38 weeks) and late-term (39 to 40 weeks) segments. The data from Grobman et al dealing with late-term pregnancies unexpectedly showed that delivery at 39 weeks not only was safe, but also was associated with better outcomes compared to expectant management in late-term normal pregnancies.1

    However, the study by Tita et al regarding early-term deliveries should give pause to anyone wishing to stray into the land of uncomplicated early-term pregnancies with this approach — even if there is documentation of pulmonary maturity.

    It was surprising that during the study period, as many as 259 uncomplicated early-term patients had amniotic fluid testing for pulmonary maturity and that the 180 who tested positive delivered early. Some of these patients even took steroids for good measure (again, with a positive test). Despite the loaded hand, infants of these patients trended toward having more respiratory distress syndrome and a significantly enhanced chance of having TTN, along with other non-pulmonic adverse neonatal events. One must wonder if there really was something different about these overtly “normal” fetuses and infants who were targeted for early delivery. Nevertheless, the results of this study strongly imply that tinkering too much with the length of pregnancy does not seem to pan out.

    REFERENCES

    1. Grobman WA, Rice MM, Reddy UM, et al. Labor induction versus expectant management and low-risk nulliparous women. N Engl J Med 2018;379:513-523.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    OB/GYN Clinical Alert

    View PDF
    OB/GYN Clinical Alert (Vol. 35, No. 8) – December 2018
    December 1, 2018

    Table Of Contents

    Are There Risks With Early-term Birth?

    Opportunistic Salpingectomy at the Time of Cesarean Delivery for Postpartum Permanent Contraception

    Help-seeking Behavior for Pelvic Floor Dysfunction

    Venous Thromboembolism Risk After Abortion

    Begin Test

    Buy this Issue/Course

    OB/GYN Clinical Alert’s Editor Jeffrey T. Jensen, MD, MPH, reports that he is a consultant for and receives grant/research support from Bayer, Merck, ContraMed, and FHI360; he receives grant/research support from Abbvie, HRA Pharma, Medicines 360, and Conrad; and he is a consultant for the Population Council. Peer Reviewer Catherine Leclair, MD; Nurse Planner Marci Messerle Forbes, RN, FNP; Editorial Group Manager Terrey L. Hatcher; Executive Editor Leslie Coplin; and Editor Jonathan Springston report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing